Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized Active-controlled Study of AMG 162 in Breast Cancer Subjects With Bone Metastasis Who Have Not Previously Been Treated With Bisphosphonate Therapy.

NCT00091832 is registered in ClinicalTrials.gov with Amgen as lead sponsor.

NCT NCT00091832
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00091832 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized Active-controlled Study of AMG 162 in Breast Cancer Subjects With Bone Metastasis Who Have Not Previously Been Treated With Bisphosphonate Therapy.
Lead sponsor
Amgen
Phase
Phase 2
Overall status
Completed
Start date
September 30, 2004
Completion date
October 31, 2006
Enrollment
255 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

bone metastases in subjects with advanced breast cancer, breast cancer, metastases